Telangiectasia

Telangiectasia refers to small, dilated blood vessels near the surface of the skin or mucous membranes. These vessels can appear as red, blue, or purple lines and are often referred to as “spider veins” or “broken capillaries.”

 Differential diagnoses (DD) for telangiectasia:

1. Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome)

2. Ataxia-Telangiectasia

3. Systemic Sclerosis (Scleroderma)

4. Lupus Erythematosus

5. Dermatomyositis

6. Chronic Sun Damage

7. Rosacea

8. Acne Rosacea

9. Ehlers-Danlos Syndrome

10. Nevus simplex (salmon patch)

11. Venous Malformations

12. Drug-Induced Telangiectasia

13. Alcoholic Liver Disease

14. Pregnancy

15. Idiopathic Telangiectasia

Diagnosis

Diagnosis is typically made through a physical examination by a healthcare provider. In some cases, additional tests may be conducted to determine underlying causes, especially if associated with systemic conditions.

Treatment

1. Laser Therapy:
   • Laser treatments can effectively reduce or eliminate the appearance of telangiectasia.
2. Sclerotherapy:
   • A procedure where a solution is injected into the affected veins to collapse them.
3. Topical Treatments:
   • Certain topical medications may help improve the appearance of telangiectasia, especially in conditions like rosacea.
4. Lifestyle Modifications:
   • Avoiding triggers such as sun exposure, extreme temperatures, and certain skin irritants can help manage symptoms.

Prevention

• Protect skin from excessive sun exposure using sunscreen and protective clothing.
• Maintain a healthy lifestyle, including a balanced diet and regular exercise.
• Manage underlying health conditions that may contribute to the development of telangiectasia.

References

1. McAllister, K.A. et al. (1994). “Endoglin, a TGF-beta receptor, is defective in hereditary hemorrhagic telangiectasia.” Nature Genetics, 8(3), 345-351. DOI:10.1038/ng1094-345
2. Kligman, A.M. (1989). “The role of ultraviolet light in the pathogenesis of skin aging.” Journal of Investigative Dermatology, 93(1), 1-5. DOI:10.1111/1523-1747.ep12464612
3. Kahn, S. et al. (2000). “Hormonal influences on the development of telangiectasia.” Journal of the American Academy of Dermatology, 43(4), 685-688. DOI:10.1067/mjd.2000.109054
4. Wilkin, J. et al. (2004). “Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea.” Journal of the American Academy of Dermatology, 50(6), 907-912. DOI:10.1016/j.jaad.2004.01.020
5. Alster, T.S., & Tanzi, E.L. (2003). “Laser treatment of telangiectasia.” Dermatologic Surgery, 29(1), 1-5. DOI:10.1046/j.1524-4725.2003.29001.x
6. Weiss, R.A. et al. (2000). “Sclerotherapy for the treatment of telangiectasia.” Dermatologic Surgery, 26(5), 421-426. DOI:10.1046/j.1524-4725.2000.99080.x
7. Draelos, Z.D. (2005). “The role of topical agents in the treatment of rosacea.” Journal of Drugs in Dermatology, 4(5), 563-568.